EuroQol (EQ-5D) health utility scores for patients with migraine

被引:47
作者
Xu, Ruifeng [1 ,2 ]
Insinga, Ralph P. [2 ]
Golden, Wendy [3 ]
Hu, X. Henry [3 ]
机构
[1] Merck & Co Inc, N Wales, PA 19454 USA
[2] Merck Res Labs, Dept Hlth Econ Stat, N Wales, PA USA
[3] Merck & Co Inc, Global Human Hlth, Global Outcomes Res & Reimbursement, Whitehouse Stn, NJ USA
关键词
Migraine; Headache; EQ-5D; Health utility score; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; CHRONIC MEDICAL CONDITIONS; UNITED-STATES; INDEX SCORES; PROPHYLACTIC TREATMENT; AMERICAN MIGRAINE; DOUBLE-BLIND; POPULATION; TOPIRAMATE;
D O I
10.1007/s11136-010-9783-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Previous studies have reported health utilities for migraine patients as generally measured between migraine attacks, but health utility data for within a migraine attack are unavailable. We evaluated within-attack health utilities among acute migraine patients experiencing different grades of headache severity. We examined data for 330 20-65-year-old adults, in good physical health, who had 1-6 moderate/severe migraine attacks per month in the 2 months prior to the screening visit. Data were collected from a multicenter, double-blind study of a treatment for acute migraine in the United States. The EQ-5D system was used to measure generic health status at baseline and 24 h post-treatment within an acute migraine attack, and patients were also asked to rate their pain level at these time points (no, mild, moderate, or severe pain). The D1 time-trade-off scoring algorithm for the U.S. population was applied. Confidence intervals were estimated by bootstrap methods. The study population was 88% women and 78% white ethnicity, with 60% of subjects over age 40. The disutility of mild migraine pain was estimated to be 0.140 (95% CI: 0.0848, 0.1940), with a disutility for moderate migraine pain of 0.186 (95% CI: 0.1645, 0.2053) and for severe migraine pain of 0.493 (95% CI: 0.4100, 0.5654). Within-attack disutilities estimated for migraine in this study are much greater than those reported for migraine when evaluated as a chronic health condition (e.g., valuations collected at random time points). These data can be of value in adapting results from clinical trials of migraine interventions to cost-utility policy analyses.
引用
收藏
页码:601 / 608
页数:8
相关论文
共 37 条
  • [1] [Anonymous], 2004, CEPHALALGIA S1, V24, P9
  • [2] On the (not so) constant proportional trade-off in TTO
    Attema, Arthur E.
    Brouwer, Werner B. F.
    [J]. QUALITY OF LIFE RESEARCH, 2010, 19 (04) : 489 - 497
  • [3] A case-control study on excessive daytime sleepiness in episodic migraine
    Barbanti, P.
    Fabbrini, G.
    Aurilia, C.
    Vanacore, N.
    Cruccu, G.
    [J]. CEPHALALGIA, 2007, 27 (10) : 1115 - 1119
  • [4] The migraine cycle: Patient burden of migraine during and between migraine attacks
    Brandes, Jan Lewis
    [J]. HEADACHE, 2008, 48 (03): : 430 - 441
  • [5] Migraine frequency and health utilities: Findings from a multisite survey
    Brown, Jeffrey S.
    Neumann, Peter J.
    Papadopoulos, George
    Ruoff, Gary
    Diamond, Merle
    Menzin, Joseph
    [J]. VALUE IN HEALTH, 2008, 11 (02) : 315 - 321
  • [6] The impact of migraine prevention on daily activities:: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials
    Dahlof, Carl
    Loder, Elizabeth
    Diamond, Merle
    Rupnow, Marcia
    Papadopoulos, George
    Mao, Lian
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2007, 5 (1)
  • [7] MIGRAINE PATIENTS EXPERIENCE POORER SUBJECTIVE WELL-BEING/QUALITY OF LIFE EVEN BETWEEN ATTACKS
    DAHLOF, CGH
    DIMENAS, E
    [J]. CEPHALALGIA, 1995, 15 (01) : 31 - 36
  • [8] Topiramate improves health-related quality of life when used to prevent migraine
    Diamond, M
    Dahlöf, C
    Papadopoulos, G
    Neto, W
    Wu, SC
    [J]. HEADACHE, 2005, 45 (08): : 1023 - 1030
  • [9] Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study
    Diener, H-C
    Bussone, G.
    Van Oene, J. C.
    Lahaye, M.
    Schwalen, S.
    Goadsby, P. J.
    [J]. CEPHALALGIA, 2007, 27 (07) : 814 - 823
  • [10] Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial
    Diener, Hans-Christoph
    Agosti, Reto
    Allais, Gianni
    Bergmans, Paul
    Bussone, Gennaro
    Davies, Brendan
    Ertas, Mustafa
    Lanteri-Minet, Michel
    Reuter, Uwe
    Del Rio, Margarita Sdnchez
    Schoenen, Jean
    Schwalen, Susanne
    van Oene, Joop
    [J]. LANCET NEUROLOGY, 2007, 6 (12) : 1054 - 1062